U.S. Continuous Glucose Monitoring Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

U.S. Continuous Glucose Monitoring Market was valued at USD 4.9 billion in 2024 and is estimated to grow at a CAGR of 16.2% to reach USD 22 billion by 2034.

This strong growth is largely influenced by the rising diabetes burden across the country, the introduction of over-the-counter CGM systems, the rapid adoption of telehealth and remote patient monitoring, and the increasing acceptance of home-based health technologies. Continuous glucose monitoring emerges as a preferred solution due to its ability to deliver real-time data and actionable insights. These devices consist of wearable sensors, transmitters, and receivers that provide continuous glucose measurements while sending alerts to users. The integration of digital platforms further boosts their adoption, as patients and clinicians can share data seamlessly for improved disease management. Unlike traditional methods that depend on fingerstick samples, CGM solutions utilize sensors placed beneath the skin to track glucose levels around the clock. Their transformation from clinical tools into consumer-oriented devices is also driving adoption among both diabetic and non-diabetic users, strengthening market expansion and creating new opportunities in preventive healthcare and metabolic wellness.

The transmitter segment generated USD 2.2 billion in 2024 and is estimated to reach USD 9.8 billion by 2034. Transmitters act as a crucial link in CGM systems by wirelessly sending glucose data from the sensor to smartphones, receivers, or insulin pumps. Attached to the sensor, these devices make real-time glucose sharing possible, ensuring continuous monitoring and timely alerts. Their growing role in enabling seamless connectivity and cloud integration continues to push this segment forward.

The hospitals segment held a 10.1% share in 2024. With healthcare systems adopting digital and patient-focused models, CGM devices are being increasingly integrated across care settings. Real-time glucose tracking is particularly beneficial for patients with unstable or complex glucose fluctuations, as it provides a consistent stream of data that aids quick medical interventions and reduces risks associated with delayed monitoring.

Key participants in the U.S. Continuous Glucose Monitoring Market include Abbott Laboratories, Dexcom, A. Menarini Diagnostics, F. Hoffmann-La Roche, Insulet Corporation, i-SENS, Glucovation, Medtronic, Nemaura Medical, Senseonics, and Sinocare. Companies in the U.S. continuous glucose monitoring industry are adopting multiple strategies to reinforce their market positioning. Continuous innovation remains a top priority, with firms investing heavily in R&D to develop smaller, longer-lasting, and more affordable CGM devices. Expansion of distribution networks and partnerships with pharmacies and digital health platforms are also being pursued to improve accessibility. Many players are enhancing their ecosystem by integrating CGMs with insulin delivery systems, wearable apps, and telehealth platforms to create comprehensive solutions for patients and providers.